Allianz Asset Management’s Enzo Biochem, Inc. ENZ Stock Holding History

Allianz Asset Management’s Portfolio ENZ Stock Details ENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-305,383	Closed	-$1.67M	–	2731
2018 Q1	$1.67M	Sell	305,383 -92,957	-23%	-$655K	﹤0.01%	2002
2017 Q4	$3.25M	Sell	398,340 -20,797	-5%	-$199K	﹤0.01%	1813
2017 Q3	$4.39M	Buy	419,137 +73,064	+21%	+$811K	﹤0.01%	1680
2017 Q2	$3.82M	Buy	346,073 +326,445	+1,663%	+$3.04M	﹤0.01%	1713
2017 Q1	$164K	Buy	+19,628	New	+$138K	﹤0.01%	2549
2015 Q2	–	Sell	-818,151	Closed	-$2.41M	–	2526
2015 Q1	$2.41M	Sell	818,151 -84,458	-9%	-$276K	﹤0.01%	1464
2014 Q4	$4.01M	Buy	902,609 +57,785	+7%	+$276K	﹤0.01%	1292
2014 Q3	$4.35M	Buy	844,824 +302,232	+56%	+$1.61M	0.01%	1130
2014 Q2	$2.85M	Buy	542,592 +162,980	+43%	+$705K	﹤0.01%	1077
2014 Q1	$1.58M	Buy	+379,612	New	+$1.3M	﹤0.01%	1284

Other funds holding ENZ

EGA

Evermore Global Advisors Summit, New Jersey $26.3M AUM 7.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Allianz Asset Management's ENZ Position: Q2 2018 in Review

Allianz Asset Management sold out of Enzo Biochem, Inc. (ENZ) in Q2 2018, closing a stake of 305,383 shares — an estimated $1.67M sold.

Allianz Asset Management first reported a position in ENZ in Q1 2014 and held it in 10 quarters. The position peaked at $4.39M in Q3 2017. 97 funds tracked by Wall St. Rank hold ENZ as of Q2 2018.

Allianz Asset Management reported no remaining Enzo Biochem, Inc. position as of Q2 2018 after selling out during the quarter.
Allianz Asset Management sold 305,383 Enzo Biochem, Inc. shares in Q2 2018, an estimated $1.67M.
Allianz Asset Management first reported a position in Enzo Biochem, Inc. in Q1 2014 and held it in 10 quarters.
Allianz Asset Management's Enzo Biochem, Inc. position peaked at $4.39M in Q3 2017.
97 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q2 2018.

Based on Allianz Asset Management's 13F filing for Q2 2018, filed 13 Aug 2018.